Proteostasis Dysregulation in Pancreatic Cancer

Show full item record



Permalink

http://hdl.handle.net/10138/328900

Citation

Arpalahti , L , Haglund , C & Holmberg , C I 2020 , Proteostasis Dysregulation in Pancreatic Cancer . in R Barrio , J D Sutherland & M S Rodriguez (eds) , PROTEOSTASIS AND DISEASE: FROM BASIC MECHANISMS TO CLINICS : From basic Mechanisms to Clinics . Advances in Experimental Medicine and Biology , vol. 1233 , Springer , Cham , pp. 101-115 . https://doi.org/10.1007/978-3-030-38266-7_4

Title: Proteostasis Dysregulation in Pancreatic Cancer
Author: Arpalahti, Leena; Haglund, Caj; Holmberg, Carina I
Other contributor: University of Helsinki, Department of Biochemistry and Developmental Biology
University of Helsinki, HUS Abdominal Center
University of Helsinki, Department of Biochemistry and Developmental Biology
Barrio, Rosa
Sutherland, James D.
Rodriguez, Manuel S.










Publisher: Springer
Date: 2020
Language: eng
Number of pages: 15
Belongs to series: PROTEOSTASIS AND DISEASE: FROM BASIC MECHANISMS TO CLINICS From basic Mechanisms to Clinics
Belongs to series: Advances in Experimental Medicine and Biology
ISBN: 978-3-030-38265-0
978-3-030-38266-7
DOI: https://doi.org/10.1007/978-3-030-38266-7_4
URI: http://hdl.handle.net/10138/328900
Abstract: The most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), has a dismal 5-year survival rate of less than 5%. Radical surgical resection, in combination with adjuvant chemotherapy, provides the best option for long-term patient survival. However, only approximately 20% of patients are resectable at the time of diagnosis, due to locally advanced or metastatic disease. There is an urgent need for the identification of new, specific, and more sensitive biomarkers for diagnosis, prognosis, and prediction to improve the treatment options for pancreatic cancer patients. Dysregulation of proteostasis is linked to many pathophysiological conditions, including various types of cancer. In this review, we report on findings relating to the main cellular protein degradation systems, the ubiquitin-proteasome system (UPS) and autophagy, in pancreatic cancer. The expression of several components of the proteolytic network, including E3 ubiquitinligases and deubiquitinating enzymes, are dysregulated in PDAC, which accounts for approximately 90% of all pancreatic malignancies. In the future, a deeper understanding of the emerging role of proteostasis in pancreatic cancer has the potential to provide clinically relevant biomarkers and new strategies for combinatorial therapeutic options to better help treat the patients.
Subject: 26S PROTEASOME
AUTOPHAGOSOME FORMATION
Autophagy
Biomarkers
DOWN-REGULATION
DUCTAL ADENOCARCINOMA
Deubiquitinating enzyme
E3 UBIQUITIN LIGASES
E3 ubiquitin-ligase
PROTEASOME INHIBITORS
PROTEIN
Pancreatic cancer
Pancreatic ductal adenocarcinoma
Proteasome
Proteostasis
REGULATORY T-CELLS
STELLATE CELLS
TUMOR-SUPPRESSOR
Ubiquitin-mediated proteolysis
3111 Biomedicine
1182 Biochemistry, cell and molecular biology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Proreostasis_in ... review_Holmberg_270619.pdf 22.17Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record